P
TERN

&Partners’s Terns Pharmaceuticals TERN Stock Holding History

&Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$233K Buy
+4,428
New +$182K ﹤0.01% 2156

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

&Partners's TERN Position: Q1 2026 in Review

&Partners opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 4,428 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #2156 among its holdings.

317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • &Partners held 4,428 shares of Terns Pharmaceuticals worth $233K as of Q1 2026.
  • Terns Pharmaceuticals was a new &Partners position in Q1 2026.
  • Terns Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2156 holding.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.